Contents

Search

hypoxia-inducible factor prolyl hydroxylase; Egl nine homolog; HIF-prolyl hydroxylase (EGLN)

Function: - oxygen-dependent proteasomal degradation of hypoxia inducible factor Pharmacology: - HIF prolyl hydroxylase inhibitors stabilize HIF, which in turn stimulate endogenous erythropoietin production

Related

hypoxia inducible factor

Specific

Egl nine homolog 1; hypoxia-inducible factor prolyl hydroxylase 2; HIF-PH2; HIF-prolyl hydroxylase 2; HPH-2; prolyl hydroxylase domain-containing protein 2; PHD2; SM-20 (EGLN1, C1orf12, PNAS-118, PNAS-137) Egl nine homolog 2; estrogen-induced tag 6; hypoxia-inducible factor prolyl hydroxylase 1; HIF-PH1; HIF-prolyl hydroxylase 1; HPH-1; prolyl hydroxylase domain-containing protein 1; PHD1 (EGLN2, EIT6) Egl nine homolog 3; hypoxia-inducible factor prolyl hydroxylase 3; HIF-PH3; HIF-prolyl hydroxylase 3; HPH-3; prolyl hydroxylase domain-containing protein 3; PHD3 (EGLN3)

General

hydroxylase; monooxygenase metalloprotein

Properties

MOTIF: active site metal ion-binding site

References

  1. UniProt :accession Q96KS0-
  2. UniProt :accession Q9GZT9
  3. UniProt :accession Q9H765
  4. Chertow GM, Pergola PE, Farag YMK Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med 2021; 384:1589-1600. April 29 PMID: 33913637 https://www.nejm.org/doi/full/10.1056/NEJMoa2035938